

PartnerRe

PartnerRe

(99.72% of voting rights; 100% interest in common shareholder's equity through EXOR Nederland)



Data presented and commented below are derived from PartnerRe's consolidated financial information for the

Year
 Net premiums written (a)
 Net investment return (b)
 Net income attributable to PartnerRe common shareholders (c)

(a) PartnerRe uses a combined ratio to measure results for the Non-life P&C and Specialty segments. The combined ratio for 2019 was 100.3% compared to 101.9% for 2018. Net premiums written for 2019 increased to \$6.9 billion compared to \$5.8 billion in 2018. Non-life net premiums written for 2019 increased to \$6.9 billion compared to \$5.8 billion in 2018. The Non-life combined ratio was 100.3% for the full year 2019 compared to 101.9% for 2018. The improvement in the combined ratio was primarily due to a decrease in the Life and Health allocated underwriting result. The Life and Health allocated underwriting result was a profit of \$73 million in 2019 compared to a profit of \$86 million in 2018. Net investment return for 2019 was \$1,352 million, or 7.7%, which included net investment income of \$449 million. Net realized and unrealized investment gains of \$887 million for the full year 2019 included net realized and unrealized investment gains of \$434 million on fixed maturities and short-term investments. Other Income Statement items

Other income was \$15 million for the full year 2019 compared to \$50 million for 2018. During the fourth quarter of 2019, other income was \$15 million compared to \$50 million for 2018. Other expenses of \$370 million (expense ratio of 5.7%) for the full year 2019 increased by \$64 million when compared to 2018. Net foreign exchange losses were \$87 million for the full year 2019, driven by the depreciation of the U.S. dollar against the Euro. Interest expense of \$40 million for the full year 2019 compared to \$43 million for 2018. During the second quarter of 2019, interest expense was \$20 million compared to \$21 million for 2018. Preferred dividends of \$46 million paid in 2019 were comparable to 2018.

Income tax expense was \$53 million on pre-tax income of \$989 million in 2019 compared to an income tax benefit of \$10 million in 2018.

Balance sheet and capitalization
 Total investments and cash and cash equivalents were \$17.8 billion at 31 December 2019, up 9.4% compared to 31 December 2018. Cash and cash equivalents, fixed maturities and short-term investments, which are government issued or investment grade, were \$17.8 billion at 31 December 2019 compared to \$16.3 billion at 31 December 2018.

The average credit rating of the fixed income portfolio increased to AA as of 31 December 2019 compared to A as of 31 December 2018. There were no dividends declared and paid to common shareholders in the fourth quarter of 2019 and fourth quarter of 2018.

Total capital was \$8.7 billion at 31 December 2019, up 9.2% compared to 31 December 2018, primarily due to the increase in common shareholder's equity (or book value) of \$6.6 billion and tangible book value of \$6.0 billion at 31 December 2019 compared to \$7.9 billion and \$5.9 billion at 31 December 2018.

Dividends Paid to EXOR
 During 2019, PartnerRe declared and paid to Exor Nederland N.V. common share dividends of \$200 million compared to \$200 million in 2018.

Reconciliation of reported US GAAP financial information to IFRS financial information used for line-by-line comparison
 The differences between the US GAAP net income (\$890 million) and the IFRS net income (\$894 million) are in the following table:

2020 Outlook
 PartnerRe believes that overall, reinsurance will broadly remain a cyclical market, albeit of less amplitude, primarily driven by the global economic environment.

2020 P&C Segment Outlook
 During the 1 January 2020 renewals, PartnerRe focused on portfolio optimization and improving profit margins. As a result of the persisting competition and excess capacity in the industry, it is not possible to forecast if improvements in the combined ratio will be achieved in 2020.

2020 Specialty Segment Outlook
 During the 1 January 2020 renewals, PartnerRe focused on portfolio optimization and improving profit margins. As a result of the persisting competition and excess capacity in the industry, it is not possible to forecast if improvements in the combined ratio will be achieved in 2020.

2020 Life and Health Outlook
 The 1 January 2020 renewal for Life business is not considered significant, as only a limited portion of the premium is expected to be written in 2020. Management expects moderate continued growth in PartnerRe's Life portfolio in 2020 assuming constant foreign exchange rates.

Periodi correlati:
 FY 2018



